Abbott (ABT): healthcare and rate exposure

How global shocks reach ABT

None of the tracked sector channels map to Abbott (Health Care), so only geography applies. Stories centered on the United States register as exposure, because the company is registered in the United States.

Direction is a tendency across cycles, not a forecast. Sector mapping uses the Finnhub industry classification; geography uses country of registration, not revenue by region.

What actually moves Abbott

Rates matter more than a defensive label suggests, because of a deal that is still mostly a plan. Total debt was $12.9 billion at the end of 2025, about $3.0 billion of it due in 2026, and most notes are fixed. The floating piece to watch is a yen term loan. Abbott also plans to borrow about $20 billion for Exact Sciences and has a $20 billion bridge commitment. That future coupon is the rate exposure, not the current stack.

Trade and geopolitics run through a business that is already mostly abroad. About 61% of sales are outside the United States, and emerging markets are about 37%. The filing now says tariffs can move inflation, exchange rates and the supply chain. It also names Russia-Ukraine sanctions. Diagnostics has already felt China, including volume-based procurement, and COVID-19 testing sales have shrunk to a small line.

The less obvious mix is that Medical Devices, led by FreeStyle Libre, is now nearly half of sales, while Established Pharmaceuticals are branded generics sold only outside the US. A tariff on devices and a currency move in emerging-market drugs are different events. Infant-formula litigation sits beside both and will not appear on a macro badge.

Drawn from the annual filing cited below. Not a forecast and not investment advice.

What Abbott sells and where it earns

Abbott makes medical devices, diagnostic tests, nutrition products and branded generic drugs. Net sales in 2025 were $44.33 billion, up 5.7%. Medical Devices is now nearly half the company at $21.39 billion, or 48%, and grew 12.6%. Diabetes Care, mainly the FreeStyle Libre glucose sensors, was the largest single line at $8.00 billion. Diagnostics brought in $8.94 billion, or 20%, and shrank for another year: COVID-19 testing sales fell to $297 million from $747 million in 2024 and $1.6 billion in 2023, and the filing also cites weak conditions in China, including volume-based procurement. Nutrition, which includes Similac infant formula and Ensure, was $8.45 billion, or 19%. Established Pharmaceuticals, branded generics sold only outside the US, was $5.54 billion, or 12% (segments sum to 99% after rounding). Sales outside the US were about 61% of the total and emerging markets about 37%. In November 2025 Abbott agreed to buy Exact Sciences for about $21 billion in equity value, which would take it into cancer diagnostics.

Customer concentration

The 10-K says Abbott has no single customer whose loss would have a material adverse effect on the company. Products are sold through wholesalers, distributors, hospitals, pharmacies, retailers and government agencies, and directly to consumers for some nutrition and diabetes products.

Debt

Total debt was $12.9 billion at December 31, 2025, of which about $3.0 billion matures in 2026. The debt is mostly fixed rate notes; the main floating piece is a 92.0 billion yen term loan due June 2029 that resets quarterly off TIBOR. Abbott plans to borrow about $20 billion to fund the Exact Sciences deal and has a $20.0 billion bridge loan commitment as backup.

Risk factors that moved this year

• Acquisition debt is new. The FY2025 filing adds a risk factor that roughly $20 billion of borrowing for Exact Sciences, against $12.9 billion of existing debt, could reduce Abbott's flexibility to respond to changing business conditions.
• Tariffs got more space. The filing now says tariffs and other trade measures could push up inflation, move exchange and interest rates and disrupt Abbott's global supply chain, with about 61% of sales outside the US.
• Infant formula litigation remains prominent. As of January 31, 2026 there were 1,760 pending lawsuits alleging Abbott's preterm infant formula caused necrotizing enterocolitis. Abbott won summary judgment in the first three federal bellwether cases in 2025, but a $495 million Missouri jury award from July 2024 is still on appeal.

How this changes the exposure read

A healthcare template treats Abbott as defensive, which mostly holds, but the channels are specific. Trade/tariff risk is real because 61% of sales are outside the US and supply chains cross borders, and the filing now spells that out. Conflict risk reaches it through emerging markets, about 37% of sales, and the Russia-Ukraine sanctions it names. Chip/export rules matter only through electronics in devices and sensors. Oil shocks are a modest input and freight cost. Rates/Fed matter more than usual because it plans about $20 billion of new borrowing for Exact Sciences. Credit stress is a minor channel.

Source: Abbott 10-K, FY2025. Checked 2026-10-07. Figures are from the filing and may differ from the live stats above.

What is moving it now

Key stats

Recent filings

Related tickers